Vertex CF Drug Combo Significantly Improves Lung Function

Vertex Pharmaceuticals Inc says results from two Phase 3 studies of its lumacaftor-ivacaftor drug combination showed statistically significant improvements in lung function (ppFEV1) in cystic fibrosis patients (12+) who have two copies of the F508del mutation.


Market Analysis: Aerosol Therapy

As the number of chronic lung patients continues to grow, today’s aerosol therapy products are providing high-quality, cost-efficient medication delivery.


Electromed Partners On Launch Of New Children’s Book

Electromed Inc has joined in the launch of a new children’s book, Healthy Choices, Happy Kids: Making Good Choices with Everyday Care, and will include a free copy of the book with all SmartVest shipments for newly prescribed patients 10 years old and younger (while supplies last).

Patient using an nnd Medical spirometer

Increasing Access To Spirometry

Initiatives across the country are expanding access to quality spirometry, a key component in the proper diagnosis and treatment of respiratory conditions like COPD and asthma.